
ChemoCentryx: A Biotech Stock Well Worth the Risk
Published on May 9, 2022
In the wake of its first quarter earnings report, ChemoCentryx ran as much as 25% on Friday as the broader market fell. The move could mark an important inflection point...

In the wake of its first quarter earnings report, ChemoCentryx ran as much as 25% on Friday as the broader market fell. The move could mark an important inflection point...